Aclarion receives us patent to protect expanded applications of magnetic resonance spectroscopy (mrs) data processing to identify pain and infection biomarkers throughout the body

Recent notice of allowance is for aclarion's 24th issued us patent propionic acid (pa) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an intervertebral disc  patent will expand aclarion's proprietary rights to use mrs to measure propionic acid as a biomarker for the identification of potential infection and pain throughout the body broomfield, colo., feb. 11, 2025 (globe newswire) -- aclarion, inc., (“aclarion” or the “company”) (nasdaq: acon, aconw), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today it has received a notice of allowance from the united states patent and trademark office (uspto) for its 24th issued us patent.
ACON Ratings Summary
ACON Quant Ranking